Article Information
History
- June 4, 2020.
Article Versions
- You are currently viewing Version 1 of this article (June 4, 2020 - 02:51).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Melinda Wang1,4,
- Xiaojia Guo, PhD1,4,
- Hyung J Chun, MD1,4,
- Alfred Ian Lee, MD, PhD1,4,
- Charles Cha, MD2,4,
- Fred Gorelick, MD1,3,4,# and
- Gary V Desir, MD1,4
- 1Department of Medicine, New Haven, CT and VA CT Health Care, West Haven, CT
- 2Department of Surgery, New Haven, CT and VA CT Health Care, West Haven, CT
- 3Department of Cell Biology, New Haven, CT and VA CT Health Care, West Haven, CT
- 4Department of Yale School of Medicine New Haven, CT and VA CT Health Care, West Haven, CT
- ↵#Correspondence should be addressed to
Gary Desir M.D. Section of Nephrology, Department of Medicine Yale School of Medicine P.O. Box 208029 New Haven, CT 06520–8029 Voice (203) 785–4119 E-Mail: gary.desir{at}yale.edu
Posted June 04, 2020.
Decreased plasma levels of the survival factor renalase are associated with worse outcomes in COVID-19
